Who is using Auvelity for depression?
A. Muzyk, F. Syed, Junjun Cong, Herriot Tabuteau, Yang Zhao
Video Journal of Biomedicine December 17, 2025 DOI: 10.1080/vjbm-2024-0006 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort Peer reviewed |
|---|---|
| Sample size | 22,000 |
| Population | Adults with major depressive disorder in the United States |
| Interventions | Auvelity (dextromethorphan HBr and bupropion HCL 45 mg/105 mg extended-release tablets) |
| Dose | 45 mg/105 mg extended-release tablets |
| Topics | Depression |
| Key findings | Patients across a wide range of demographics began using Auvelity, with about one-third starting it as monotherapy. |
Abstract
Abstract This study is the first to analyse real-world use of Auvelity (dextromethorphan HBr and bupropion HCL, 45 mg/105 mg extended-release tablets) for treating major depressive disorder (MDD) in the United States. Researchers reviewed medical records of over 22,000 adults, examining factors like age, gender, insurance, and previous depression treatments. Findings revealed that patients across a wide range of demographics began using AUVELITY. About one-third of patients started using it alone, as a monotherapy, and a variety of healthcare professionals prescribed it. This research offers insights into real-world use of AUVELITY. Video Article Read the transcript
Comparable studies
Other observational and cohort studies on depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Metacognitive awareness and prevention of relapse in depression: Empirical evidence. Residually depressed patients and nondepressed controls; recovered depressed patients | 2002 | Observational cohort with intervention components | |
| Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Patients with treatment-resistant depression | 2017 | Observational cohort | n = 19 |
| Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report Patients with a depressive disorder | 2015 | Observational study | |
| Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder Patients with treatment-resistant major depressive disorder | 2012 | Observational cohort | n = 30 |
| Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome Healthy controls and actively depressed patients with treatment-resistant depression... | 2017 | Observational cohort | n = 59 |